MARK1 and carcinoma: In a recent review study, through a detailed analysis of 15 molecular characteristics by Pawel Sadlecki et al., the genetic progression of borderline ovarian tumors towards low‐grade carcinoma via the ‘low‐grade pathway’ was attributed to mutations along the RAS/RAF/MEK/MARK pathway [11].